Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 800 restricted stock units (RSUs) to one newly hired employee, effective October 31, 2025, under the company’s 2022 Inducement Stock Incentive Plan.

The award was made as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years with 33 1/3% vesting on each anniversary of the grant date, subject to continued service through each vesting date.

NEWTON, Mass., Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of October 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302597816.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What did Karyopharm (KPTI) announce on November 3, 2025 regarding RSUs?

Karyopharm announced a grant of 800 RSUs to one newly hired employee, effective October 31, 2025.

Why did Karyopharm issue the 800 RSUs under Nasdaq Listing Rule 5635(c)(4)?

The RSU award was issued as an inducement material to the new employee entering employment, consistent with Nasdaq Rule 5635(c)(4).

What is the vesting schedule for the KPTI 800 RSU award granted October 31, 2025?

The RSUs vest over three years, with 33 1/3% vesting on each of the three consecutive anniversaries of the grant date, subject to continued service.

Will the 800 RSU grant to a single hire materially dilute KPTI shareholders?

The announcement discloses the 800 RSU grant only and does not state any share count or dilution percentage.

Is continued employment required for the KPTI RSUs to vest?

Yes. Vesting is subject to the employee's continued service as an employee or other service provider through each vesting date.